REGENXBIO encountered a significant regulatory obstacle when the FDA issued a complete response letter regarding its biologics license application for RGX-121, an investigational gene therapy targeting mucopolysaccharidosis II (MPS II), commonly known as Hunter syndrome. As reported by Pharmaceutical Technology, the decision represents a setback for the biotech company’s decade-long development effort to bring this treatment to patients suffering from this progressive, life-threatening genetic disorder.
The Regulatory Impasse
Despite receiving accelerated approval pathway status in May 2025, which typically expedites the review process for therapies addressing serious conditions with unmet medical needs, the FDA determined that current evidence does not meet the threshold for approval. The agency’s concerns centered on three principal areas that REGENXBIO must now address to advance its application.
First, the FDA questioned whether study eligibility criteria adequately distinguished between patients with neuronopathic versus attenuated disease presentations. This distinction matters considerably for establishing appropriate patient populations and predicting treatment outcomes. Second, regulators expressed doubt about whether the external control data based on natural disease history sufficiently matched the characteristics of the study population being treated with RGX-121. Third, and perhaps most significantly, the FDA challenged whether cerebrospinal fluid heparan sulphate D2S6 represents a valid surrogate endpoint capable of predicting actual clinical benefit to patients.
Navigating the Ultra-Rare Disease Challenge
The FDA presented multiple potential pathways for REGENXBIO to pursue, each presenting substantial logistical and scientific complications. Options included conducting an entirely new clinical study, enrolling and treating additional patients with extended follow-up periods, or incorporating an untreated control arm into future trials. For a company developing treatments for an ultra-rare condition like MPS II, each approach involves considerable complexity and resource investment.
REGENXBIO maintains that throughout the BLA review process, the company proactively addressed FDA concerns with comprehensive responses and supplementary data. The company even engaged independent global MPS and biomarker experts to collaborate with the FDA during ongoing discussions, demonstrating commitment to transparency and scientific rigor. However, the regulatory agency concluded that these efforts fell short of demonstrating substantial effectiveness evidence necessary for approval.
Path Forward
Rather than accepting defeat, REGENXBIO is mounting a strategic response. The company intends to request a Type A meeting with the FDA, a formal consultation mechanism allowing companies and regulators to align on development strategies moving forward. During this meeting, REGENXBIO plans to present additional data from global MPS II experts alongside extended clinical follow-up information to strengthen its effectiveness demonstration and clarify patient population characteristics.
The company’s leadership expressed profound disappointment with the decision, characterizing it as “devastating for the families of boys living with this progressive, life-threatening disease.” Despite regulatory setbacks, REGENXBIO remains confident in RGX-121’s potential and the robustness of accumulated evidence. The company aims to resubmit its application as expeditiously as possible.
This regulatory challenge comes as REGENXBIO strengthens its position through partnerships, having established an $810 million strategic collaboration with Japan-based Nippon Shinyaku to advance multiple MPS-targeted gene therapies, signaling continued commitment to this therapeutic area despite current approval delays.
